Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGAM1 | P18669 | 2/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.36 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22011095 | 0.96 | PGAM1 (0.38) | PGAM1LTB4RHMGCRKDM4EALDH1A1 | |
| SCHEMBL22010784 | 0.92 | ABCB1 (0.34) | PGAM1HMGCRKDM4EALDH1A1HPGD | |
| SCHEMBL22011226 | 0.89 | HMGCR (0.36) | HMGCRKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL22011083 | 0.88 | PGAM1 (0.35) | PGAM1LTB4R | |
| SCHEMBL22010810 | 0.88 | PGAM1 (0.35) | PGAM1LTB4R | |
| SCHEMBL22010796 | 0.88 | L3MBTL1 (0.35) | PGAM1LTB4RALDH1A1 | |
| SCHEMBL22010811 | 0.88 | KDM4E (0.36) | PGAM1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL22010968 | 0.87 | PGAM1 (0.42) | PGAM1LTB4R | |
| SCHEMBL22011181 | 0.87 | PGAM1 (0.42) | PGAM1LTB4R | |
| SCHEMBL22010964 | 0.86 | KDM4E (0.37) | PGAM1KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662378-B2 | Compound having fluorodibenzofuran ring, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662378-B2 | Compound having fluorodibenzofuran ring, liquid crystal composition and liquid crystal display device | YBX1, ZKSCAN2, RCC1 | PGAM1 4829/4885LTB4R 1149/4885HMGCR 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.